AZN: Imfinzi Combination Improves Disease-Free Survival In Phase III High-Risk Bladder Cancer Trial

(RTTNews) - AstraZeneca Plc. (AZN, AZN.L) announced that results from the POTOMAC Phase III trial showed that one year of treatment with its Imfinzi (durvalumab), combined with standard Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, significantly improved disea https://www.nasdaq.com/articles/azn-imfinzi-combination-improves-disease-free-survival-phase-iii-high-risk-bladder-cancer